Literature DB >> 19254280

Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.

Morgan Rouprêt1, Vincent Hupertan, Eva Comperat, Sarah J Drouin, Véronique Phé, Evanguelos Xylinas, David Demanse, Mathilde Sibony, Francois Richard, Olivier Cussenot.   

Abstract

OBJECTIVE: To establish the predictive accuracy of the Kattan preoperative nomogram by comparing predictions at 5 years with actual progression in patients who had a radical prostatectomy (RP).
MATERIALS AND METHODS: We reviewed the data for 928 patients treated by RP as a first-line treatment for localized prostate cancer, between 1994 and 2005. Recurrence was defined as one prostate-specific antigen (PSA) level of >0.4 ng/mL. The 5-year progression-free probability (PFP) rate was evaluated on censured data using the Kaplan-Meier method. Relationships between all predictor variables included in the Kattan nomogram (PSA level, biopsy Gleason scores and clinical stage) and survival were evaluated by Cox proportional-hazards regression analysis. The discriminating ability of the nomogram was assessed by the concordance index (c-index). Bootstrapping was used to assess confidence intervals (CIs), and then the calibration was assessed.
RESULTS: The median follow-up was 60 months. Overall, 177 (19%) patients had a recurrence; the 5-year PFP rate (95% CI) was 80.9 (78-83)%. Of the three variables included in the nomogram, all were associated with recurrence in a multivariate analysis (P < 0.001). The c-index (95% CI) was only 0.664 (0.584-0.744). In general, the nomogram was not well calibrated.
CONCLUSIONS: There was a discrepancy between the predicted PFP as estimated by the Kattan nomogram and actual relapse in this group of patients. Clinicians should be aware that the nomogram is less accurate when used outside the population used to formulate the nomogram. Although more accurate tools are needed, the Kattan nomogram is still the best choice for urologists so far.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254280     DOI: 10.1111/j.1464-410X.2009.08473.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study.

Authors:  Alexandra Masson-Lecomte; Vincent Hupertan; Eva Comperat; Christophe Vaessen; Emmanuel Chartier-Kastler; Olivier Cussenot; Marc-Olivier Bitker; Morgan Rouprêt
Journal:  World J Urol       Date:  2010-11-12       Impact factor: 4.226

Review 2.  Prostate cancer nomograms: a review of their use in cancer detection and treatment.

Authors:  R J Caras; Joseph R Sterbis
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

Review 3.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

4.  Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.

Authors:  Firas Abdollah; Deepansh Dalela; Akshay Sood; Jesse Sammon; Wooju Jeong; Burkhard Beyer; Nicola Fossati; Craig G Rogers; Mireya Diaz-Insua; James Peabody; Alexander Haese; Francesco Montorsi; Markus Graefen; Alberto Briganti; Mani Menon
Journal:  World J Urol       Date:  2016-02-12       Impact factor: 4.226

5.  Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram.

Authors:  D R Yates; V Hupertan; P Colin; A Ouzzane; A Descazeaud; J A Long; G Pignot; S Crouzet; F Rozet; Y Neuzillet; M Soulie; T Bodin; A Valeri; O Cussenot; M Rouprêt
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.